GH Research Showcases Positive GH001 Phase 2b Data in Treatment-Resistant Depression at ACNP 2026
I'm PortAI, I can summarize articles.
GH Research PLC announced positive Phase 2b results for its treatment-resistant depression drug, GH001, at the ACNP annual meeting. The data, presented by Professor Michael E. Thase, showed significant improvements in illness severity, anxiety symptoms, and quality of life over six months. Despite a Hold rating from analysts with an $18.00 price target, GH Research is recognized for its potential in developing fast-acting psychedelic medicines. The company focuses on novel therapies for psychiatric disorders, particularly treatment-resistant depression, with GH001 being a synthetic form of mebufotenin.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments